Bambuterol

From The Lycaeum
Jump to: navigation, search
</th></tr></th></tr>
Bambuterol
200px
Systematic (IUPAC) name
(RS)-5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat. Unknown
Legal status Prescription only
Routes Oral
Pharmacokinetic data
Bioavailability 20%
Metabolism Hepatic, extensive
Further metabolized to terbutaline by plasma cholinesterase
Half-life 13 hours (bambuterol)
21 hours (terbutaline)
Excretion Renal
Identifiers
CAS number 81732-46-9 7pxY
ATC code R03CC12
PubChem CID 54766
DrugBank DB01408
ChemSpider 49466 7pxY
UNII Y1850G1OVC 7pxN
KEGG D07377 7pxY
ChEBI CHEBI:553827 7pxN
ChEMBL CHEMBL521589 7pxY
Chemical data
Formula C18H29N3O5 
Mol. mass 367.44 g/mol
 14pxN (what is this?)  (verify)

Bambuterol is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. Commercially, the AstraZeneca pharmaceutical company produces and markets bambuterol as Bambec and Oxeol (INN).[1]

Indications

As other LABAs, bambuterol is used in the long-term management of persistent asthma.[1] It should not be used as a rescue medication for short-term relief of asthma symptoms.

Contraindications

Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people with renal impairment, but dose adjustments are necessary.[1]

Adverse effects

The adverse effect profile of bambuterol is similar to that of salbutamol, and may include fatigue, nausea, palpitations, headache, dizziness and tremor.[1]

Interactions

Concomitant administration of bambuterol with corticosteroids, diuretics, and xanthine derivatives (such as theophylline) increases the risk of hypokalemia (decreased levels of potassium in the blood).[2]

Bambuterol acts as a cholinesterase inhibitor, and can prolong the duration of action of suxamethonium (succinylcholine) and other drugs whose breakdown in the body depends on cholinesterase function.[1] Butyrylcholinesterase activity returns to normal approximately two weeks after bambuterol is stopped.[3] It can also enhance the effects of non-depolarizing neuromuscular blockers, such as vecuronium bromide.[2]

References

  1. 1.0 1.1 1.2 1.3 1.4 Sweetman, Sean C., ed. (2009). "Bronchodilators and Anti-asthma Drugs". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. pp. 1115–16. ISBN 978-0-85369-840-1. 
  2. 2.0 2.1 Sweetman (2009), pp. 1132–33.
  3. Sitar DS (October 1996). "Clinical pharmacokinetics of bambuterol". Clin Pharmacokinet 31 (4): 246–56. PMID 8896942. doi:10.2165/00003088-199631040-00002. 
      
Personal tools
Namespaces

Variants
Actions
Navigation
Forums
Lycaeum IRC Chat
TheAntiDrug Diaspora
Starting Points
Tools